Clinical study, network pharmacology, and molecular docking of Kunxian capsule in treating idiopathic membranous nephropathy
KX is a safe and effective treatment option for IMN and can effectively improve serum albumin and 24 h urine protein levels in patients with IMN. This study preliminarily reveals the possible mechanism of KX in the treatment of IMN and provides a theoretical basis for future clinical research.
Authors
- Geng Tian (ORCID: https://orcid.org/0000-0001-5752-4436)
- Xinyu Gao (ORCID: https://orcid.org/0000-0003-2205-6067)
- Xuehong Lu (ORCID: https://orcid.org/0000-0002-0380-2477)
- Lihua Liu (ORCID: https://orcid.org/0000-0003-2252-8407)
- Jia Lv
- Libing He
Institutions
- Second Affiliated Hospital of Jilin University (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-02-06
- DOI
- https://doi.org/10.3389/fmed.2025.1506972
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- People's Government of Jilin Province
- Department of Science and Technology of Jilin Province
- Health Commission of Jilin Province